Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus On
- PDF / 401,238 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 74 Downloads / 167 Views
ORIGINAL RESEARCH
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis Ataru Igarashi . Barnaby Hunt
. Lars Wilkinson . Jakob Langer .
Richard F. Pollock
Received: July 22, 2020 / Published online: September 1, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: In the head-to-head trial (SUSTAIN 7), the novel, injectable, once-weekly GLP-1 analogue semaglutide showed superiority in both glycemic outcomes and body weight reduction, compared with once-weekly dulaglutide in the treatment of type 2 diabetes (T2D). However, no economic evaluation using these data has yet been conducted in the Japanese setting. The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12794195. A. Igarashi Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Yokohama, Japan A. Igarashi Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan B. Hunt (&) R. F. Pollock Ossian Health Economics and Communications GmbH, Basel, Switzerland e-mail: [email protected] L. Wilkinson Novo Nordisk A/S, Søborg, Denmark J. Langer Novo Nordisk Pharma Ltd., Tokyo, Japan
approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data. Methods: Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets (‘‘cost of control’’). Responder endpoint definitions consisted of single, dual, and triple composite endpoints related to glycemic control, body weight, and hypoglycemia outcomes. The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only. Results: Treatment with once-weekly semaglutide 0.5 mg was associated with a lower cost and a lower cost per patient treated to target for all endpoints, compared with once-weekly dulaglutide 0.75 mg. For each JPY 1 spent on bringing patients to target with once-weekly semaglutide 0.5 mg, JPY 1.58, JPY 1.44, JPY 1.60, JPY 2.10, and JPY 2.33 would need to be spent on once-weekly dulaglutide 0.75 mg to achieve an equivalent outcome for endpoints of HbA1c B 6.5%, HbA1c \ 7.0%, HbA1c \ 7.0% without hypoglycemia, and no weight gain, weight loss C 5%, and C 1.0% HbA1c reduction and C 3.0% weight loss, respectively. Conclusions: These findings suggest that onceweekly semaglutide is a cost-effective treatment option compared with once-weekly dulaglutide for patients with T2D in Japan. In the future, this finding should be extrapolated to traditional long-term cost-effectiveness analysis,
Adv Ther (2020) 37:4446–4457
using common outcomes such as quality-adjusted life years. Keywords: Cost–be
Data Loading...
